Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
Asgard Therapeutics is a Biotechnology Company.
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 13 different industry categories.
Among tracked funding rounds, Harmony Biosciences received $248.0M in a Post Ipo Secondary round. Novo Holdings's total known invested capital is $15.2B.
Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.
Recent Novo Holdings portfolio additions include Claris Biotherapeutics, Newleos Therapeutics, Aligos Therapeutics, Commit Biologics, Coave Therapeutics. These companies were founded in 2020 or later.